- BriaCell Therapeutics (TSX:BCT), a Canadian biotechnology stock developing cancer immunotherapies, announced the resolution of the lung metastasis first reported in February in a 78-year-old woman with metastatic breast cancer
- The achievement comes two months after the patient enrolled in the ongoing phase 1/2 study of Bria-OTS, the company’s personalized off-the-shelf cancer immunotherapy
- BriaCell stock is up by 23.56 per cent on the news trading at C$9.44
BriaCell Therapeutics (TSX:BCT), a Canadian biotechnology stock developing cancer immunotherapies, announced the resolution of the lung metastasis first reported in February in a 78-year-old woman with metastatic breast cancer.
The achievement comes two months after the patient enrolled in the ongoing phase 1/2 study of Bria-OTS, a personalized off-the-shelf cancer immunotherapy, with study data at four months also substantiating stable disease elsewhere.
According to Thursday’s news release, the patient received the lowest dose level under the study, showing “the potentially promising activity of the Bria-OTS platform as monotherapy.”
Leadership insights
“Despite recent advancements with antibody-drug-conjugates and immune check point inhibitors, many patients, including those with hormone-receptor-positive (HR+) disease, like BriaCell’s first OTS patient, have very few options,” Neal S. Chawla, director at the Sarcoma Oncology Center, Santa Monica, California, and principal investigator for the Bria-OTS study, said in a statement. “We are thrilled with our initial data with single agent Bria-OTS showing rapid and strong anti-tumor activity in an HR+ patient and look forward to continuing this novel approach in patients with metastatic breast cancer and other cancers.”
“This unprecedented anti-cancer response in the first patient dosed with Bria-OTS is an important milestone for us and provides early validation of BriaCell’s personalized immunotherapy approach,” added William V. Williams, BriaCell’s president and chief executive officer.
About BriaCell Therapeutics
BriaCell is a clinical-stage biotechnology company developing cancer immunotherapies.
BriaCell stock (TSX:BCT) is up by 26.44 per cent on the news trading at C$9.66 as of 11:14 am ET.
Join the discussion: Find out what everybody’s saying about this cancer immunotherapy stock on the BriaCell Therapeutics Corp. Bullboard and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: BriaCell Therapeutics)
